Specific features of current intraperitoneal therapy in patients with ovarian cancer

• Main Authors: A. G. Kedrova (Author), S. A. Levakov (Author), S. E. Krasil'nikov (Author), T. A. Maksimenko (Author), V. I. Voznesenskiy (Author), A. V. Gerasimov (Author), D. A. Astakhov (Author), V. V. Kosyy (Author), O. E. Nechaeva (Author)
• Format: Book
• Published: ABV-press, 2016-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. Today there are 3 trends in favor of intraperitoneal (IP) chemotherapy: maintenance of its potential 5- and 10-year survival benefit in patients with ovarian cancer (OC); advantages of the IP administration of drugs even after nonoptimal surgery; enhancement of the efficiency of chemothe...